August 2026– date –
-
NueCell Bio Launches as Translational Partner to Accelerate Cell Therapies from Discovery to GMP Manufacturing
PR Newswire USA Overview NueCell Bio has officially launched as a new "translational partner" dedicated to accelerating cell therapy products from scientific discovery through GMP-compliant manufacturing and clinical readiness. The compa... -
Opus Genetics Completes Patient Enrollment in Phase III Trial of Gene Therapy for Inherited Retinal Dystrophy
Precision Medicine Online USA Overview Opus Genetics has completed patient enrollment in its Phase III clinical trial for a gene therapy targeting severe inherited retinal dystrophy. This milestone signifies a critical step towards poten... -
Vertex’s CASGEVY Gene Therapy Expands FDA Approval to Pediatric Patients 2+ for Sickle Cell and Beta-Thalassemia; Umoja’s In Vivo CAR-T for Solid Tumors Enters Clinic
BioInsights USA Overview July 2026 marked significant progress in gene and cell therapy access, with Vertex Pharmaceuticals' CASGEVY receiving expanded FDA approval for pediatric patients aged 2 and older with sickle cell disease and tra... -
Umoja Biopharma Initiates Phase 1/2 Trials for In Vivo CAR-T Therapies UB-VV400 and UB-VV500 Targeting B-Cell Malignancies and Multiple Myeloma
Gene Therapy Net (ClinicalTrials.gov) USA Overview Umoja Biopharma is set to initiate Phase 1/2 clinical trials for its investigational in vivo CAR-T cell therapies, UB-VV400 for recurrent/refractory B-cell malignancies and UB-VV500 for ... -
FDA Issues Warnings as No Approved Therapeutic Exosomes Exist in 2026 Amidst Reports of Adverse Events
OmniGenix USA Overview As of 2026, the U.S. FDA has not approved any therapeutic exosome products, issuing warnings against unauthorized sales due to reported adverse events. A 2025 review of clinical trials from 2014-2024 indicated favo... -
BlossomHill and Latigo Secure $496 Million in Combined IPOs, Fueling Clinical-Stage Cancer and Non-Opioid Pain Therapies
Endpoints News USA Overview BlossomHill Therapeutics and Latigo Biotherapeutics successfully completed their IPOs, raising a combined total of $496 million, with $150 million for BlossomHill and $346 million for Latigo. These substantial... -
Replimune’s Tudriqev Secures FDA Accelerated Approval for Advanced Melanoma After Two Prior Rejections
BioPharma Dive USA Overview Replimune has achieved FDA accelerated approval for its advanced melanoma drug, Tudriqev, following two prior rejections and eventual support from an FDA advisory committee. The drug is approved for use in com... -
After Two Rejections, Replimune’s Melanoma Drug RP1 Secures Coveted FDA Accelerated Approval for Combination Therapy
Endpoints News USA Overview Replimune has successfully obtained FDA accelerated approval for its advanced melanoma drug, RP1 (marketed as Tudriqev), following a year-long dispute and two prior rejections. The approval, based on a Phase 2... -
Private Investors Reroute $8.8 Billion into Emerging Market AI Data Centers, Reshaping Global AI Infrastructure Strategy
Briefs Finance USA Overview In the first half of 2026, private investors poured a significant $8.8 billion into AI projects in developing nations, primarily funding data centers and AI companies. Regions like India, China, Mexico, Africa... -
KKR Acquires Medtech Giant Integer Holdings for $5.7 Billion, Signaling AI’s Growing Influence on Biotech Investment
Fierce Biotech USA Overview KKR has sealed a $5.7 billion deal to take Integer Holdings, a prominent medical technology manufacturer, private. This significant M&A transaction underscores a broader trend of large-scale deals within t...
